These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 10464128

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.
    Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, Sandler RS, Hanauer SB.
    Aliment Pharmacol Ther; 2014 Jan; 39(2):163-75. PubMed ID: 24237037
    [Abstract] [Full Text] [Related]

  • 23. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
    Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M.
    Cochrane Database Syst Rev; 2009 Jan 21; (1):CD000067. PubMed ID: 19160175
    [Abstract] [Full Text] [Related]

  • 26. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
    Bouguen G, Sninsky C, Tang KL, Colombel JF, DʼHaens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn WJ.
    Inflamm Bowel Dis; 2015 Mar 21; 21(3):606-14. PubMed ID: 25581826
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X, Serre-Debeauvais F, Phelip JM, Faucheron JL, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B.
    Aliment Pharmacol Ther; 2005 Apr 01; 21(7):829-39. PubMed ID: 15801918
    [Abstract] [Full Text] [Related]

  • 29. Lack of effect of intravenous azathioprine on time to respond for steroid treated Crohn's disease.
    Carter MJ, Lobo AJ.
    Gut; 2001 Mar 01; 48(3):295-6. PubMed ID: 11171815
    [No Abstract] [Full Text] [Related]

  • 30. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
    Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF.
    J Gastroenterol Hepatol; 2007 Feb 01; 22(2):268-74. PubMed ID: 17295882
    [Abstract] [Full Text] [Related]

  • 31. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA, McDonald JW, Feagan BG.
    Cochrane Database Syst Rev; 2003 Feb 01; (1):CD003459. PubMed ID: 12535475
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
    Gastroenterology; 2006 Apr 01; 130(4):1054-61. PubMed ID: 16618399
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N, Koukouratos T, Anastasiou J, Giakoumis M, Triantos C, Tsolias C, Theocharis G, Karamanolis DG.
    Eur J Gastroenterol Hepatol; 2015 Apr 01; 27(4):436-41. PubMed ID: 25874518
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.